Gary started in the IP profession in 1990 as an Examiner of Patents with the Australian Patent Office (now IP Australia).
In 1991, he moved to Sydney and took up a position with a then leading Sydney based IP firm. In 1994, Gary took up a position with Wrays.
Gary’s practice extends across the following areas in biotechnology and pharmaceuticals:
- advice towards strategic IP development in start-up companies and SME’s;
- drafting patent applications;
- prosecution of patent applications;
- opinion work, including freedom to operate opinions, opinions for regulatory approval of pharmaceuticals as well as general due diligence opinion; and
- contentious matters including:
- Patent oppositions; and
- Litigation – court actions (infringement and revocation actions) in Australia and New Zealand.
Some of the leading contention matters that Gary has been retained to act in:
- Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513 (Acted for Kirin Amgen);
- Pfizer Overseas Pharmaceuticals v Eli Lilly and Co (2005) 225 ALR 416 (Acted for Eli Lilly and Co);
- Genentech, Inc v Ludwig Institute for Cancer Research and Human Genome Sciences, Inc  APO 20 (5 June 2006) (Acted for Human Genome Sciences Inc); and
- Danisco A/S v Novozymes A/S (No 2)  FCA 282 (29 March 2011) (Acted for Danisco A/S)
- Eli Lilly and Company Limited v Apotex Pty Ltd  FCA 214
A more detailed list of cases can be provided on request.